Lineage Cell Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

LCTX$1.04-3.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Lineage	$(64,384)	$(15,336)
Net income (loss) attributable to noncontrolling interest	125	4
Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:
Issuance costs for common stock warrant liabilities	183	—
Loss on impairment of intangible asset	14,840	—
Loss on marketable equity securities, net	1	21
Accretion of income on marketable debt securities	(10)	(184)
Depreciation and amortization expense	513	436
Change in right-of-use assets and liabilities	(41)	(31)
Amortization of intangible assets	—	22
Stock-based compensation	3,654	3,762
Change in fair value of warrant liability	36,992	—
Foreign currency remeasurement	(1,721)	309
Changes in operating assets and liabilities:
Accounts receivable	511	339
Prepaid expenses and other current assets	1,077	891
Accounts payable and accrued liabilities	(188)	(1,778)
Deferred revenue	(5,593)	(5,201)
Net cash used in operating activities	(14,041)	(16,746)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of marketable equity securities	—	18
Purchases of marketable debt securities	—	(8,761)
Maturities of marketable debt securities	2,000	4,000
Purchase of equipment	(123)	(200)
Net cash (used in) provided by investing activities	1,877	(4,943)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from employee options exercised	487	229
Proceeds from exercise of warrants	319	—
Common shares received and retired for employee taxes paid	(15)	(23)
Proceeds from sale of common shares under ATM, net of offering costs	1,276	68
Proceeds from sale of common shares under registered direct financing, net of offering costs	—	13,889
Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs	5,232	—
Payment of financed insurance premium	(684)	—
Payment of finance lease liabilities	(44)	(40)
Net cash provided by financing activities	6,571	14,123
Effect of exchange rate changes on cash, cash equivalents and restricted cash	216	(120)
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(5,377)	(7,686)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period	46,354	35,992
At end of the period	$40,977	$28,306
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	$27	$6
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Property and equipment expenditures in accounts payable	$25	$11
Fair value of warrant liability recognized upon issuance in registered direct financing	$2,205	$—
Derivative warrant liability reclassified to share capital on exercise of warrants	$187	$—
Receivable from exercise of stock options	$159	$—
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	$40,463	$27,750
Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies))	514	556
Total cash, cash equivalents, and restricted cash	$40,977	$28,306

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.